Cue Health Inc (CE) (HLTHQ) Quote

HLTH changed to HLTHQ, bankruptcy. Delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

HLTH: Maybe they just sell their 'Health Care' stuff on GRAND CAYMAN???

I sold that while back

HLTH: Maybe now it's, "buy buy buy while u can"???

up 40 percent after hours..

Bankrupt company sell sell sell while u can

Sellothon Continues

Last run to 14 cents

Almost tie with FFIE

Sellothon Continues

How Low Will it Go

Wonder will it Break a Billion

500 million shares at 11am

Just found this what going on here?

HLTH: Their "news" --- about pondering the trashing of their entire Firm --- did NOT seem too inspiring to me EITHER. (Nevertheless, watch it SOAR to 500%+++ --- just to SPITE me personally!!!)

Just going off the recent 8k

In accordance with the Notice, the Company has until July 22, 2024 to submit a plan of compliance

And they do not intend to submit a plan

For a fact? ....Thanks!!!

Ya got about 90 days to pump it up till OTC bound July 22

LoL, a 100-bagger???

They have issues............

Z

HLTH at .16 cents but won’t last long take profits

HLTH under 10cents

nice

HLTH............................https://stockcharts.com/h-sc/ui?s=HLTH&p=W&b=5&g=0&id=p86431144783

Good morning so far

$HLTH
https://x.com/hannahadad8890/status/1740862233825996848?s=61

The need for quick and accurate infectious disease diagnosis will facilitate the use of new techniques such as “syndromic infectious disease testing”.  Rather than looking for and isolating certain pathogens individually, syndromic infectious disease testing examines a wide range of clinical “syndromes,” or symptoms, to identify an infectious disease.
Traditional tests often calls for long lab analyses, and can only identify one pathogen at a time. On the other hand, syndromic infectious disease tests such as Multiplex PCR (mPCR) can correctly identify the genetic material of numerous pathogens in a much shorter time frame, granting physicians a much faster and more precise infectious disease diagnostic tool.
The Multiplex PCR Tests that Cue Health is developing and soon to offer; including Flu + RSV + COVID; Chlamydia + Gonorrhea; Herpes + Mpox; that can accurately determine the genetic code of numerous pathogens for syndromic testing; will allow physicians to deploy more accurate treatments, which can significantly reduce infectious disease severity.

New e-commerce channels especially for high-growth healthcare products and services sector are rapidly evolving as indicated by Walmart and Amazon among a larger pipeline of retailer-to-healthcare providers that has grown in the last few years. Pharmacy chains such as CVS and Walgreens are a few others that have greatly invested in becoming primary care providers. Amazon in particular has made significant moves forward toward becoming a key player in the healthcare industry, inspire of the fact withdrawing “Amazon Care” in late 2022, it came back in early 2023 and bought out One Medical for almost $4 billion. Meanwhile Walmart has also made progress toward becoming a major provider in this market, launching brick-and-mortar clinics across American with the objective of becoming the “neighborhood health destination”, with plans to add 28 new locations in 2024, and in talks to purchase a majority stake in ChenMed, a primary care provider. Providing the backbone of such enterprises are healthcare e-commerce platforms such as NextPlat Corp, which is helping to popularize virtual healthcare and which could result in the majority of the population preferring to access all the healthcare services and products that they need via the internet. Noteworthy is Cue Health’s presence in the Telehealth and healthcare e-commerce with its Cue Care and Cue Pharmacy. A buy-out candidate for one of these large retailers?

The World Health Organization is monitoring a surge of respiratory illnesses among children in China, that Chinese health authorities reported are “due to Mycoplasma pneumoniae pneumonia since May, and RSV, adenovirus and influenza virus since October”; and attributed to the increase in respiratory diseases with the lifting of COVID-19 restrictions, as the country is in its first full winter without such restrictions. At the same time in the US, the CDC reports that “only 14% of Americans have received the latest COVD-19 vaccine”, which is below where the agency would like vaccine uptake to be. "Here's the bottom line: COVID-19 vaccine uptake is lower than we'd like to see, and most people will be without the added protection that can reduce the severity of COVID-19," the agency stated.

Cue management has been impressively executing on key strategic priorities beginning with exceeding the $150M cost reduction goal with $165M realized and ahead of schedule; and a number of new products in the pipeline that will provide continued test menu expansion for the Cue Health Monitoring System; and notably Flu + COVID multiplex; and Cue RSV and Cue FLU molecular tests; all under active FDA review; and with one or more approval letters anticipated in the respiratory inflection season; all on the same cartridge system platform that can be turned on immediately in Cue’s automated manufacturing system. Significantly all products are integrated into Cue Care, a same day POC solution enabling Telehealth and prescription subscription and delivery with Cue Pharmacy. At the same time leveraging Cue Lab the mail in at-home test kits, these will become very meaningful parts of the business over the next year and years beyond to profitability. With continued total revenue growth, as indicated by Q3 2023 exceeding expectations with $17.5M reported; new initiatives gaining momentum; with opportunities to bolster cash position and extend the operating runway, and various marketing channels that will offer continued commercialization and growth in 2024; the prospects of profitability looks within reach shortly thereafter!

Cue Health should take Sherlock Biosciences' playbook with its acquition of Sense Biodection's "Veros", an instrument-free rapid molecular test platform with results comparable to qRT-PCR lab results, that would accelerated reaching the global consumers. And there’s been a lot of speculation that 2023 will see increased M&A activity in the life sciences industry; maybe Cue Health will lead this trend in the private market?

There is no question that the Cue Health Monitoring System is best-in-class POCT device available on the market today. However Cue Health can not achieve a global market reach unless it has a product offering closer to the World Health Organization (WHO) guidelines for “ASSURED” - affordable and off-the-shelf, sensitive, specific, user friendly, reliable, efficient and time-saving; field deployable; and most significantly, instrument-free with no external electrical and optical system requirement, POC device. The broadly available paper-based NAAT devices do meet most of the ASSURED criteria, they are inexpensive, easily disposable, responsive to biomolecule conformations and interactions, and are good sample and reagent carriers, making them ideal substrates for use in remote and resource-poor setting. It is possible to envision developing an integrated paper/membrane based microfluidic device for instrument-free RNA isolation, reverse transcription, amplification and detection that can be performed at room temperature. The successful development of this type of PRT device by Cue Health, either through partnership, acquisition, licensing is a step forward towards the goal of developing a complete instrument-free integrated NAAT system for POC diagnosis that can have broad global market reach and establish preeminent brand recognition with full product complement.

I have the Cue Reader and Cue Covid Test Cartridges and its a breeze to use: and with no contact with the buffer, reagent, or reaction chamber and nothing to “mess-up”; nicely designed and manufactured; and with a great interaction app; and made with “Apple-like” packaging presentation. However just like Apple, its expensive, and I use it sparingly, preferring to get the cheaper “antigen” LFT strips, with no brand preferences other than the “free ones” when they were available or the “cheap ones” to stock up when they go on sale at the local chain drug store.
This is a great POCT machine and with a strong value proposition for institutions. However the private consumer is being left behind (and as such money left on the table) The future of diagnostic testing for this segment of the market is going to depend on innovative electromechical design, for "entirely self-contained and disposable" OTC and advance "next generation" chemistry to allow AMBIENT and NEAR INSTANTANEOUS REACTIONS, BATTERY POWERED, AND EASY TO READ. Start-ups and their backers are rushing to get this done, and sometimes with Gates Foundation Grants where they are willing to give up a portion of the global market (with “open-access” and global licensing agreements). I am anxiously awaiting for something like this (before the competition sweeps past with a low COGS personal consumer product with):
No instrument or reader;
No external power supply;
Results shown on a high-contrast display.
Maybe a “partnering deal”?

Lets stop for a moment and recognized what has transpired, prior to COVID-19 you could only test for HIV at home, and approval was a 10-year process. The next phase of this, is now taking the momentum for COVID-19 home testing with EUA's, and appyling it to a broader range of issues, a broader range of pathogens; and with 510K's (substantially equivalent) and De Novo (not present substantial risk to user/patient) approvals now taking months instead of years (as with a PMA). Out of necessity came reform and now a sweet spot for Cue and with that has an overwhelming advantage!

Points to ponder … Cue current valuation (P/S) is significantly above the S&P 500 index average and a current price risk rating below the S&P 500; and as such would provide high levels of diversification to a portfolio similar to the broader market. However be prepared for some bumpy patches with price fluctuations more volatile than the overall market. "Be patient and think long-term"!

A TIME article on Sept 25 titled “Is It Flu, COVID-19, or RSV? How to Navigate the New World of At-Home Testing” speaks about the criticality of figuring out whether a sore throat, fever, and runny nose were caused by a cold, flu, strep, or COVID infection (and need to limit spread); and makes mention of Cue Health’s products (although with some misinformation). At this time, Flu A/B, RSV, COVID Multiplex Molecular Tests are "deep" in FDA approval reviews!

"Cue Health Anticipates Multiple Upcoming Test Launches as Q3 Revenues Fall 75 Percent" and same revenue story with other diagnostic testing businesses due to plummeting sales of COVID-19 tests (i.e. Siemens, Hologic, etc.); however they also show double digit growth in non-COVID revenue. And this is what Cue is working on with other molecular (NAAT/LAMP) tests now in FDA review!

TD Cowen just reduced target from $5 to $1.50 and near-term that’s about right. Its not a sprint, its a marathon, and now post-pandemic adoption is about alignment of clinicians, payers, and the patient; and workflow changes. Right now Cue is nibbling away on the outside for specific demographic and use case(s). Patients will always want something that is coordinated and aligned; and will not give up the face-to-face therapeutic alliance for a faceless app. So Cue’s next leg of the journey is its part in making that encounter more meaningful, more efficient and more engaging; and help answer for the provider: “out of the 1000’s of patients who should come in?”. This will come as Cue’s technology is deployed for evidence-based guidelines, with “numbers that don’t lie”; and create a next generation of care experiences; that allows for patients to be in control of their data and for providers to intervene earlier, and prevent more costly outcomes (and this payers will embrace)!

3Q/23 substantially exceeded guidance at $17.5M, with improved net loss, and surpassing the cost target with annualized savings of $165M and realized ahead of time! New products in FDA review!

The need for quick and accurate infectious disease diagnosis will facilitate the use of new techniques such as “syndromic infectious disease testing”.  Rather than looking for and isolating certain pathogens individually, syndromic infectious disease testing examines a wide range of clinical “syndromes,” or symptoms, to identify an infectious disease.

Traditional tests often calls for long lab analyses, and can only identify one pathogen at a time. On the other hand, syndromic infectious disease tests such as Multiplex PCR (mPCR) can correctly identify the genetic material of numerous pathogens in a much shorter time frame, granting physicians a much faster and more precise infectious disease diagnostic tool.

The Multiplex PCR Tests that Cue Health is developing and soon to offer; including Flu + RSV + COVID; Chlamydia + Gonorrhea; Herpes + Mpox; that can accurately determine the genetic code of numerous pathogens for syndromic testing; will allow physicians to deploy more accurate treatments, which can significantly reduce infectious disease severity.

HLTH...........................https://stockcharts.com/h-sc/ui?s=HLTH&p=W&b=5&g=0&id=p86431144783

HLTH...RELODED THAT DIP

HLTH...HERE GO

shorts were 436 000 and covered a tad above 400 000....

I do think they might be onto something though. This idea of these home test that the Doctor has access to and will write a script from, could be a huge deal for some folks. (Thinking especially of those with chronic illness.)

NOT THAT A 5% share holder has much to say...they are the only company that has a FDA covid home test, but thats no big deal

THEY are definitely what frustrated me out. But again, that was their goal. 😂

thanks...not sure whats driving it...5% investor has been pushing for change...shorts did increase their positions yesterday

Nice call TrendTrade. Got to admit, I took a 4 cent profit on this one and bailed last week. Just grew frustrated and quit watching.
GLTU

HLTH READY TO BREAK OUT